oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Company profile
Ticker
ORMP
Exchange
Website
CEO
Nadav Kidron
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IGUANA VENTURES LTD, Integrated Security Technologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
Oramed Ltd. • Oramed HK Limited • Oravax Medical Inc. ...
IRS number
980376008
ORMP stock data
Latest filings (excl ownership)
8-K
Other Events
19 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Other Events
20 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
8-K
Other Events
21 Dec 23
8-K
Departure of Directors or Certain Officers
18 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Aug 21 | Aug 20 | Aug 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.47 mm | 5.47 mm | 5.47 mm | 5.47 mm | 5.47 mm | 5.47 mm |
Cash burn (monthly) | 433.00 k | 2.31 mm | 1.09 mm | 1.84 mm | 231.33 k | 1.41 mm |
Cash used (since last report) | 2.96 mm | 15.78 mm | 7.48 mm | 12.53 mm | 1.58 mm | 9.64 mm |
Cash remaining | 2.51 mm | -10.31 mm | -2.01 mm | -7.07 mm | 3.89 mm | -4.17 mm |
Runway (months of cash) | 5.8 | -4.5 | -1.8 | -3.9 | 16.8 | -3.0 |
Institutional ownership, Q4 2023
3.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 53 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 36.77 mm |
Total shares | 1.36 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Slager David Mark | 1.34 mm | $5.70 mm |
Glass Jacobson Investment Advisors | 10.54 k | $24.35 mm |
IFP Advisors | 1.50 k | $3.47 mm |
CHCO City Holding | 1.07 k | $2.46 mm |
Beacon Capital Management | 219.00 | $572.00 k |
Global Retirement Partners | 100.00 | $228.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Yehuda Reznick | Common Stock | Grant | Acquire A | No | No | 0 | 29,800 | 0.00 | 29,800 |
30 Jan 24 | Daniel Aghion | Common Stock | Grant | Acquire A | No | No | 0 | 3,750 | 0.00 | 38,820 |
4 Jan 24 | Benjamin Shapiro | Common Stock | Grant | Acquire A | No | No | 0 | 5,070 | 0.00 | 55,070 |
4 Jan 24 | Benjamin Shapiro | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 50,000 |
4 Jan 24 | Daniel Aghion | Common Stock | Grant | Acquire A | No | No | 0 | 5,070 | 0.00 | 35,070 |
4 Jan 24 | Daniel Aghion | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |